IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A <u>An isolated</u> mammalian cell which is loaded with a bacteria for the prophylaxis or therapy of a disorder <u>in a subject</u>,

wherein the cell is autologous, allogeneic or xenogeneic with the subject and is selected from the group consisting of [["]]macrophages, dentritic dendritic cells, granulocytes, lymphocytes, tumor cells and tissue cells [["]], and

wherein the bacteria harbors a recombinant DNA which codes for at least one protein.

Claim 2 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim 1, which is inactivated by irradiation or other methods.

Claim 3 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim 1, wherein the bacteria are alive, nonvirulent, virulence-attenuated, or dead.

Claim 4 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim 1, wherein the bacteria are selected from the group consisting of [["]]Mycobacterium tuberculosis, M. bovis, M. bovis strain BCG, BCG substrains, M. avium, M. <u>intracellulare intracellailare</u>, M. africanum, M. <u>kansasii kansasil</u>, M. marinum, M. ulcerans, M. avium subspecies paratuberculosis, Norcardia asteroides, other Nocardia species, Legionella pneumophila, other Legionella species, Salmonella typhi, S. typhimurium, other Salmonella species, Shigella species, Yersinia pestis, Pasteurella haemolytica, Pasteurella multocida, other Pasteurella species, Actinobacillus pleuropneumoniae, Listeria monocytogenes, L. ivanovii, Brucella abortus, other Brucella species, Chlamydia pneumoniae, Chlamydia trachomatis, Chlamydia psittaci, and Coxiella burnetii[["]].

Claim 5 (Cancelled)

Claim 6 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim <u>1</u> 5, wherein at least one active substance protein encoded by the recombinant <u>DNA</u> is produced by the bacteria with the aid of suitable promoters, or the expression thereof is under the control of a eukaryotic promoter.

Claim 7 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim 1, wherein the bacteria produces an active substance at least one protein encoded by the <u>recombinant DNA</u> that <u>is localized localizes</u> intracellularly; that is associated with a <u>membrane of the bacteria</u>, or that is secreted.

Claim 8 (Currently Amended): The <u>isolated</u> mammalian cell as claimed in claim 1, wherein the <u>active substance protein</u> is selected from the group consisting of [["]] antigens of infectious agents, antigens specific for tumors, antibodies, epitope-binding fragments of antibodies, fusion proteins, enzymes, <u>imunospuppressant-immunosuppressant</u> cytokines, immunostimulating cytokines, growth factors, and inhibitory proteins.

Claim 9 (Currently Amended): A method for the prophylaxis or therapy of <u>neoplastic</u> diseases, immune diseases, autoimmune diseases, chronic inflammations and organ <u>transplants</u> a disorder, comprising:

administrating an effective amount of a <u>an isolated</u> mammalian cell of claim 1 to a subject, wherein the active substance the bacteria produces at least one protein encoded by the recombinant DNA and/or a vaccine antigen produced by the bacteria which protein

blocks negative regulatory elements in a tumor tissue, and wherein the cell is autologous, allogeneic or xenogeneic with the subject.

Claim 10 (Previously Presented): The method of claim 9, wherein the bacteria serve as a proinflammatory stimulant in a tumor tissue.

Claim 11 (Currently Amended): The method of claim 9, wherein dendritic cells or macrophages are employed simultaneously as a carrier for the <u>protein vaccine antigen</u>.

Claim 12 (Currently Amended): The method of claim 9, wherein the <u>protein active</u> substance and/or the vaccine antigen is loaded *ex vivo* onto dentritic dendritic cells or onto the macrophages.

Claim 13 (Cancelled)

Claim 14 (Previously Presented): The method of claim 9, wherein the mammalian cell is fused to another cell which expresses a tissue antigen or a tumor antigen.

Claim 15 (Previously Presented): The method of claim 14, wherein the fused cells are autologous tumor cells.

Claim 16 (Cancelled)

Claim 17 (Currently Amended): The method of claim 9, wherein the bacteria is a microorganism that recombinant DNA comprises a heterologous nucleotide sequence foreign DNA, for producing a pharmaceutical composition.

Claim 18 (Currently Amended): The method of claim 17, wherein the foreign DNA heterologous nucleotide sequence codes for a defined protein active substance, and wherein a pharmaceutical composition is intended for the prophylaxis or treatment of a disorder neoplastic diseases, immune diseases, autoimmune diseases, chronic inflammations and organ transplants which can be prevented and/or treated with the protein active substance.

Claim 19 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the infectious agent is a virus, a bacteria, a mycoplasma, or a parasite.

Claim 20 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the enzyme is an enzyme for activating inactive precursors of a medicament.

Claim 21 (Currently Amended): The <u>isolated</u> mammalian cell of claim 20, wherein the enzyme for activating inactive precursors of a medicament is a β -glucuronidase, a phosphatase, a hydrolase, or a lipase.

Claim 22 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the <u>imunospuppressant</u> immunosuppressant cytokine is IL-10.

Claim 23 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the immunostimulating cytokine is IL-1, IL-2, IL-3, IL-6, a chemokine, or an interferon.

Claim 24 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the growth factor is G-CSF, GM-CSF, M-CSF, FGF, VEGF, or EGF.

Claim 25 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the inhibitory protein is specific for a cytokine, a chemokine, an interferon, or a growth factor.

Claim 26 (Currently Amended): The <u>isolated</u> mammalian cell of claim 8, wherein the fusion protein comprises at least one epitope-binding fragment of an antibody directed against an antigen on a tumor cell, a lymphocyte, or an endothelial cell.

Claim 27 (Currently Amended): The <u>isolated</u> mammalian cell of claim 26, wherein the lymphocyte is a T lymphocyte.

Claim 28 (Currently Amended): The <u>isolated</u> mammalian cell of claim 26, wherein the endothelial cell is a tumor endothelial cell.